Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Scenarios and speculation

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Feb 04, 2023 12:47pm

194 Views

Post# 35266829

RE:RE:RE:Scenarios and speculation

Estimated revenue of US$6 per share = US$120 per share at 20 price to earnings = US$7.35 Billion.

which aligns with the US$ 8 Billion (plus) valuation for ONCY that has been previously posted.

However etimated US$6 per share does not include the multiple indications that pelareorep could potentially be used in combination with other I/O agents AND the US$6 estimated revenues per share are EX China. So with China included the estimated revenues would be significantly greater than US$6 per share and so would ONCY's ultimate valuation.

<< Previous

Bullboard Posts

Next >>

HPQ Silicon updates shareholders on Fumed Silica Reactor developments